Clinician Participation in Cadth’s Pan-Canadian Oncology Drug Review: Contribution and Impact on Cancer Drug Funding Recommendations
Excerpt
In any given week, media headlines publicize the benefits of a new “breakthrough” cancer drug, with patients and clinicians subsequently advocating for its use. [...]
Share and Cite
Trudeau, M.; Hoskins, P.; Reiman, T.; Chambers, A.; Mai, H.; Wheatley-Price, P. Clinician Participation in Cadth’s Pan-Canadian Oncology Drug Review: Contribution and Impact on Cancer Drug Funding Recommendations. Curr. Oncol. 2017, 24, 71-74. https://doi.org/10.3747/co.24.3644
Trudeau M, Hoskins P, Reiman T, Chambers A, Mai H, Wheatley-Price P. Clinician Participation in Cadth’s Pan-Canadian Oncology Drug Review: Contribution and Impact on Cancer Drug Funding Recommendations. Current Oncology. 2017; 24(2):71-74. https://doi.org/10.3747/co.24.3644
Chicago/Turabian StyleTrudeau, M., P. Hoskins, T. Reiman, A. Chambers, H. Mai, and P. Wheatley-Price. 2017. "Clinician Participation in Cadth’s Pan-Canadian Oncology Drug Review: Contribution and Impact on Cancer Drug Funding Recommendations" Current Oncology 24, no. 2: 71-74. https://doi.org/10.3747/co.24.3644
APA StyleTrudeau, M., Hoskins, P., Reiman, T., Chambers, A., Mai, H., & Wheatley-Price, P. (2017). Clinician Participation in Cadth’s Pan-Canadian Oncology Drug Review: Contribution and Impact on Cancer Drug Funding Recommendations. Current Oncology, 24(2), 71-74. https://doi.org/10.3747/co.24.3644